These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27821553)

  • 1. Potential biomarkers to follow the progression and treatment response of Huntington's disease.
    Disatnik MH; Joshi AU; Saw NL; Shamloo M; Leavitt BR; Qi X; Mochly-Rosen D
    J Exp Med; 2016 Nov; 213(12):2655-2669. PubMed ID: 27821553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma inflammatory biomarkers for Huntington's disease patients and mouse model.
    Chang KH; Wu YR; Chen YC; Chen CM
    Brain Behav Immun; 2015 Feb; 44():121-7. PubMed ID: 25266150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
    Rodriguez-Lebron E; Denovan-Wright EM; Nash K; Lewin AS; Mandel RJ
    Mol Ther; 2005 Oct; 12(4):618-33. PubMed ID: 16019264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
    Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
    Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges of Huntington's disease and quest for therapeutic biomarkers.
    Kotrcova E; Jarkovska K; Valekova I; Zizkova M; Motlik J; Gadher SJ; Kovarova H
    Proteomics Clin Appl; 2015 Feb; 9(1-2):147-58. PubMed ID: 25290828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease.
    Acevedo-Torres K; Berríos L; Rosario N; Dufault V; Skatchkov S; Eaton MJ; Torres-Ramos CA; Ayala-Torres S
    DNA Repair (Amst); 2009 Jan; 8(1):126-36. PubMed ID: 18935984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.
    Hsiao HY; Chen YC; Chen HM; Tu PH; Chern Y
    Hum Mol Genet; 2013 May; 22(9):1826-42. PubMed ID: 23372043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington's disease patients.
    Askeland G; Dosoudilova Z; Rodinova M; Klempir J; Liskova I; Kuśnierczyk A; Bjørås M; Nesse G; Klungland A; Hansikova H; Eide L
    Sci Rep; 2018 Jun; 8(1):9817. PubMed ID: 29959348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease.
    Fisher SP; Black SW; Schwartz MD; Wilk AJ; Chen TM; Lincoln WU; Liu HW; Kilduff TS; Morairty SR
    Brain; 2013 Jul; 136(Pt 7):2159-72. PubMed ID: 23801738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of status redox with demographic, clinical and imaging parameters in patients with Huntington's disease.
    Peña-Sánchez M; Riverón-Forment G; Zaldívar-Vaillant T; Soto-Lavastida A; Borrero-Sánchez J; Lara-Fernández G; Esteban-Hernández EM; Hernández-Díaz Z; González-Quevedo A; Fernández-Almirall I; Pérez-López C; Castillo-Casañas Y; Martínez-Bonne O; Cabrera-Rivero A; Valdés-Ramos L; Guerra-Badía R; Fernández-Carriera R; Menéndez-Sainz MC; González-García S
    Clin Biochem; 2015 Dec; 48(18):1258-63. PubMed ID: 26210848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease.
    Ban JJ; Chung JY; Lee M; Im W; Kim M
    Biochem Biophys Res Commun; 2017 Jun; 488(2):316-321. PubMed ID: 28495533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease.
    Kim J; Amante DJ; Moody JP; Edgerly CK; Bordiuk OL; Smith K; Matson SA; Matson WR; Scherzer CR; Rosas HD; Hersch SM; Ferrante RJ
    Biochim Biophys Acta; 2010; 1802(7-8):673-81. PubMed ID: 20460152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficiency of Ube3a in Huntington's disease mice brain increases aggregate load and accelerates disease pathology.
    Maheshwari M; Shekhar S; Singh BK; Jamal I; Vatsa N; Kumar V; Sharma A; Jana NR
    Hum Mol Genet; 2014 Dec; 23(23):6235-45. PubMed ID: 25027318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
    Wade A; Jacobs P; Morton AJ
    Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.
    Hsiao HY; Chiu FL; Chen CM; Wu YR; Chen HM; Chen YC; Kuo HC; Chern Y
    Hum Mol Genet; 2014 Aug; 23(16):4328-44. PubMed ID: 24698979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.
    Borovecki F; Lovrecic L; Zhou J; Jeong H; Then F; Rosas HD; Hersch SM; Hogarth P; Bouzou B; Jensen RV; Krainc D
    Proc Natl Acad Sci U S A; 2005 Aug; 102(31):11023-8. PubMed ID: 16043692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease.
    Narayanan KL; Chopra V; Rosas HD; Malarick K; Hersch S
    Mol Neurobiol; 2016 May; 53(4):2132-40. PubMed ID: 25941073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huntington's disease: the current state of research with peripheral tissues.
    Sassone J; Colciago C; Cislaghi G; Silani V; Ciammola A
    Exp Neurol; 2009 Oct; 219(2):385-97. PubMed ID: 19460373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.